Blog
RSS FeedPosted by Michael Wonder on 06 Jun 2026
Adjuvanted trivalent influenza vaccine authorised for adults aged 50 and over
4 June 2026 - The MHRA has today granted a marketing authorisation for the adjuvanted trivalent influenza vaccine (Aujemflu) to protect ...
Posted by Michael Wonder on 22 May 2026
More New Zealanders could benefit from funded vaccines from 2027
21 May 2026 - PHARMAC is proposing changes that would give more New Zealanders access to funded vaccines from 2027, ...
Posted by Michael Wonder on 30 Apr 2026
Draft 2026-27 Cost Recovery Implementation Statement for listing medicines on the PBS and designated vaccines on the NIP
30 April 2026 - Consultation on the draft 2026-27 Cost Recovery Implementation Statement (CRIS) for listing medicines on the Pharmaceutical ...
Posted by Michael Wonder on 22 Apr 2026
Moderna receives European Commission marketing authorisation for mCOMBRIAX, Moderna's mRNA combination vaccine against influenza and COVID-19
21 April 2026 - mCOMBRIAX will be made available in the European Union, subject to national regulatory and access procedures ...
Posted by Michael Wonder on 20 Apr 2026
Free RSV vaccine for older Australians
19 April 2026 - The Albanese Government is introducing free Respiratory Syncytial Virus (RSV) vaccinations for older Australians to ensure ...
Posted by Michael Wonder on 07 Apr 2026
ICER releases draft evidence report on vaccines for Covid-19
7 April 2026 - Public comment period now open until 4 May 2026; requests to make oral comment during public ...
Posted by Michael Wonder on 28 Mar 2026
Bavarian Nordic submits data to EMA to extend mpox and smallpox vaccine approval to children aged 2-11 years
27 March 2026 - Submission based on topline data from clinical study, demonstrating a comparable safety profile and a non-inferior immune ...
Posted by Michael Wonder on 13 Mar 2026
GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased risk
13 March 2026 - GSK today announced that the US FDA has expanded the approved age indication of Arexvy (respiratory syncytial ...
Posted by Michael Wonder on 18 Feb 2026
Moderna announces the US FDA will initiate the review of its investigational seasonal influenza vaccine submission
18 February 2026 - Moderna has received a PDUFA goal date of 5 August 2026. ...
Posted by Michael Wonder on 18 Feb 2026
Moderna receives European Commission marketing authorisation for COVID-19 vaccine mNEXSPIKE
17 February 2026 - mNEXSPIKE is the third Moderna vaccine authorised in the European Union, strengthening the Company's respiratory vaccine ...
Posted by Michael Wonder on 12 Feb 2026
FDA refusing to review Moderna mRNA flu shot application
11 February 2026 - Moderna said on Tuesday that the FDA has refused to review its application for an mRNA flu ...
Posted by Michael Wonder on 11 Feb 2026
Moderna receives refusal to file letter from the US FDA for its investigational seasonal influenza vaccine, mRNA-1010
10 February 2026 - Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna has ...
Posted by Michael Wonder on 26 Jan 2026
GSK’s RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older
26 January 2026 - GSK today announced that its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, has been approved by ...
Posted by Michael Wonder on 23 Jan 2026
What role does equity play in Australia’s health technology assessment processes? A review of the PBAC recommendations regarding vaccines
23 January 2026 - The Australian PBAC makes recommendations to the government on the listing of vaccines on the National Immunisation ...
Posted by Michael Wonder on 22 Jan 2026
BioNTech receives FDA fast track designation for mRNA cancer immunotherapy candidate BNT113 in HPV16+ head and neck cancer
21 January 2026 - BioNTech today announced that the US FDA has granted fast track designation to BNT113, an investigational mRNA ...